Core Insights - Cencora reported quarterly earnings of $3.84 per share, exceeding the Zacks Consensus Estimate of $3.79 per share, and showing an increase from $3.34 per share a year ago, resulting in an earnings surprise of +1.32% [1] - The company achieved revenues of $83.73 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.69% and reflecting a year-over-year increase from $79.05 billion [2] - Cencora's stock has increased by approximately 53.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.05, with projected revenues of $87.22 billion, and for the current fiscal year, the EPS estimate is $17.37 on revenues of $342.35 billion [7] - The estimate revisions trend for Cencora was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Cencora belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting that the industry's outlook may impact stock performance [8] - Another company in the same industry, Ardent Health, is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year change of +121.1%, with revenues anticipated to be $1.55 billion, up 7.1% from the previous year [9][10]
Cencora (COR) Q4 Earnings and Revenues Surpass Estimates